David D. Chang
Cedars-Sinai Medical Center · 58 works · 15,580 citations · h-index 35
Top works
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- Exon amplification: a strategy to isolate mammalian genes based on RNA splicing.
- Regulation by HIV Rev depends upon recognition of splice sites
- Precise identification of individual promoters for transcription of each strand of human mitochondrial DNA
- A mammalian Mitochondrial RNA Processing Activity Contains Nucleus-Encoded RNA
- Inhibition of Stat1-mediated gene activation by PIAS1
- Priming of human mitochondrial DNA replication occurs at the light-strand promoter.
- Mouse RNAase MRP RNA is encoded by a nuclear gene and contains a decamer sequence complementary to a conserved region of mitochondrial RNA substrate
- A novel endoribonuclease cleaves at a priming site of mouse mitochondrial DNA replication.
- Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility.
- Replication priming and transcription initiate from precisely the same site in mouse mitochondrial DNA.
- Structural analysis of the interaction between the human immunodeficiency virus Rev protein and the Rev response element.
- Rack1, a Receptor for Activated Protein Kinase C, Interacts with Integrin β Subunit
- ICAP-1, a Novel β1 Integrin Cytoplasmic Domain–associated Protein, Binds to a Conserved and Functionally Important NPXY Sequence Motif of β1 Integrin
- Differential gene expression between normal and tumor-derived ovarian epithelial cells.
- Messenger RNA Transport and HIV rev Regulation
- Precise Assignment of the Light-Strand Promoter of Mouse Mitochondrial DNA: a Functional Promoter Consists of Multiple Upstream Domains
- Precise Assignment of the Heavy-Strand Promoter of Mouse Mitochondrial DNA: Cognate Start Sites Are Not Required for Transcriptional Initiation
- Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors